Carcinogenesis Advance Access originally published online on October 10, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 24, No. 12, 1919-1928,
December 2003
© Oxford University Press; all rights reserved
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz
1 Department of Pharmacology and Toxicology, and 2 Department of Pathology, Dartmouth Medical School, Hanover, NH 03755, USA, 3 Department of Pathology, Guangxi Cancer Institute, Nanning, 530027, People's Republic of China, 4 W.Harry Feinstone Center for Genomic Research, University of Memphis, Memphis, TN 38152, USA, 5 Department of Epidemiology and 6 Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
Oltipraz and related dithiolethiones constitute an important class of chemopreventive agents that enhance the expression of carcinogen detoxication and antioxidant genes. Dose–response studies were undertaken to characterize the cancer chemopreventive activities of several dithiolethiones that are at least as active as oltipraz as inducers. Inhibition of formation of pre-neoplastic lesions and formation of DNA adducts in livers of rats exposed to aflatoxin B1 (AFB1) was monitored. In the tumorigenesis experiment, the dithiolethiones were orally gavaged 3 days/week for 3 successive weeks and at four doses ranging from 0.03 to 0.3 mmol/kg body wt. AFB1 was gavaged beginning 1 week after the start of the dithiolethiones and for two successive weeks. The burden of AFB1-induced putative pre-neoplastic lesions (glutathione S-transferase-placental isoform positive foci) was quantified by light microscopy. Reduction in AFB–DNA adduct burden was assessed 24 h following the first dose of AFB1. Both the parent 1,2-dithiole-3-thione (D3T) and its 5-tert-butyl derivative were more potent inhibitors than oltipraz against these endpoints, while two of the seven tested analogs were slightly less inhibitory. D3T, the most potent dithiolethione of this series, was examined by microarray analysis for induction of hepatic genes at an intermediate chemopreventive dose (0.1 mmol/kg). Transcript levels of eight genes, including two known to detoxify aflatoxin, namely, glutathione S-transferase A5 (GSTA5) and AFB1 aldehyde reductase (AFAR) were elevated. Western analysis indicated that induction of hepatic GSTA5 and AFAR were directly related to the dose of D3T. At the highest dose of D3T (0.3 mmol/kg), protein levels of GSTA5 and AFAR were induced by 7- and 27-fold, respectively. While efficacy in humans has yet to be tested, D3T is clearly more potent than oltipraz and serves as a useful molecular probe for determining the key events associated with protection by this class of agents.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. D. Roebuck, D. N. Johnson, C. H. Sutter, P. A. Egner, P. F. Scholl, M. D. Friesen, K. J. Baumgartner, N. M. Ware, S. Bodreddigari, J. D. Groopman, et al. Transgenic Expression of Aflatoxin Aldehyde Reductase (AKR7A1) Modulates Aflatoxin B1 Metabolism but not Hepatic Carcinogenesis in the Rat Toxicol. Sci., May 1, 2009; 109(1): 41 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. T. Tran, L. Xu, V. Phan, S. B. Goodwin, M. Rahman, V. X. Jin, C. H. Sutter, B. D. Roebuck, T. W. Kensler, E.O. George, et al. Chemical genomics of cancer chemopreventive dithiolethiones Carcinogenesis, March 1, 2009; 30(3): 480 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang and R. Munday Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther., November 1, 2008; 7(11): 3470 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Aleksunes and J. E. Manautou Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease Toxicol Pathol, June 1, 2007; 35(4): 459 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Karuri, Y. Huang, S. Bodreddigari, C. H. Sutter, B. D. Roebuck, T. W. Kensler, and T. R. Sutter 3H-1,2-Dithiole-3-thione Targets Nuclear Factor {kappa}B to Block Expression of Inducible Nitric-Oxide Synthase, Prevents Hypotension, and Improves Survival in Endotoxemic Rats J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Yates, M.-K. Kwak, P. A. Egner, J. D. Groopman, S. Bodreddigari, T. R. Sutter, K. J. Baumgartner, B.D. Roebuck, K. T. Liby, M. M. Yore, et al. Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole Cancer Res., February 15, 2006; 66(4): 2488 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, J. Yan, R. Lubet, T. W. Kensler, and T. R. Sutter Identification of novel transcriptional networks in response to treatment with the anticarcinogen 3H-1,2-dithiole-3-thione Physiol Genomics, January 12, 2006; 24(2): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Pool-Zobel, V. Selvaraju, J. Sauer, T. Kautenburger, J. Kiefer, K. K. Richter, M. Soom, and S. Wolfl Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics Carcinogenesis, June 1, 2005; 26(6): 1064 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Munday and C. M. Munday Induction of phase II enzymes by 3H-1,2-dithiole-3-thione: dose-response study in rats Carcinogenesis, September 1, 2004; 25(9): 1721 - 1725. [Abstract] [Full Text] [PDF]
|
|